Literature DB >> 16476090

Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors.

L Scalone1, L G Mantovani, P M Mannucci, A Gringeri.   

Abstract

Inhibitors represent one major complication of haemophilia treatment, as they increase the risk of bleeding, physical disability and mortality. The Cost Of Care Inhibitors Study (COCIS) showed that modern strategies applied to manage patients with inhibitors adsorb high amounts of resources but provide satisfactory levels of Health-Related Quality-of-Life (HR-QoL). This paper focuses on determinants of HR-QoL in inhibitory patients. Fifty adult patients, enrolled by 11 Italian Haemophilia Centres, were clinically assessed and filled in two HR-QoL generic questionnaires: the EuroQol instrument (EQ-5D) and the Short Form-36 (SF-36). According to our results, bleeding frequency and inhibitor titres were not found associated with HR-QoL. Global HR-QoL, and in particular the physical component of wellbeing in these patients was found negatively associated with their orthopaedic condition: the EQ-5D Visual Analogue Scale (P<0.001) scores, the SF-36 domain 'physical functioning' and 'physical component summary' (P<0.01) scores were found significantly correlated with the orthopaedic joint score, even after adjusting for patients' age. These results were confirmed by those from the EQ-5D profile. To conclude, the COCIS study is the first study showing that HR-QoL in inhibitory patients is impaired by their orthopedic status, while other aspects do not seem to influence patients' global wellbeing. Our results suggest that while the management of this complication is satisfactory, the attention has now to be focused on the prevention of the orthopaedic problems in these patients, which nowadays constitute one of the most important aspects to be considered in the haemophilia care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476090     DOI: 10.1111/j.1365-2516.2006.01204.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  25 in total

1.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

2.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

3.  Emicizumab use in major orthopedic surgery.

Authors:  Craig D Seaman; Margaret V Ragni
Journal:  Blood Adv       Date:  2019-06-11

4.  Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis.

Authors:  Craig D Seaman; Margaret V Ragni
Journal:  Blood Adv       Date:  2017-07-18

5.  Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors.

Authors:  Denise E Sabatino; Steven W Pipe; Diane J Nugent; J Michael Soucie; W Craig Hooper; W Keith Hoots; Donna M DiMichele
Journal:  Haemophilia       Date:  2019-07       Impact factor: 4.287

6.  Compartment syndrome in patients with haemophilia.

Authors:  James Donaldson; Nicholas Goddard
Journal:  J Orthop       Date:  2015-05-29

7.  Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

Authors:  Junjiang Sun; Narine Hakobyan; Leonard A Valentino; Brian L Feldman; R Jude Samulski; Paul E Monahan
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

Review 8.  Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 9.  Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

Review 10.  Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.

Authors:  Abha H Athale; Maura Marcucci; Alfonso Iorio
Journal:  Cochrane Database Syst Rev       Date:  2014-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.